SEHK:1177Pharmaceuticals
China Approves LM-350 Clinical Trials; Could Be a Game Changer for Sino Biopharm (SEHK:1177)
On November 18, 2025, Sino Biopharmaceutical announced that its subsidiary LaNova Medicines received clinical trial approval in China for LM-350, a CDH17-targeting antibody-drug conjugate aimed at treating multiple gastrointestinal cancers.
This regulatory milestone marks further progress in Sino Biopharmaceutical's efforts to address significant unmet medical needs in the oncology sector through its innovative pipeline.
We’ll examine how this clinical trial approval for LM-350 shapes Sino...